• Home
  •  / Generex Biotechnology

Generex Biotechnology

OverviewSuggest Edit

Generex Biotechnology Corporation is engaged in the research, development, and commercialization of drug delivery systems and technologies. Generex has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity (with no deposit in the lungs). The Company's proprietary liquid formulations allow drugs typically administered by injection to be absorbed into the body by the lining of the inner mouth using the Company's proprietary RapidMist device.        

TypePublic
HQBurlington, CAMap
Websitegenerex.com

Recent NewsAll News

Latest Updates

Employees (est.) (Jul 2019)9(+200%)
Revenue (FY, 2019)$6.2 M(+783%)
Share Price (Feb 2021)$0.4 (+7%)
Cybersecurity ratingBMore

Key People/Management at Generex Biotechnology

Joseph Moscato

Joseph Moscato

Chief Executive Officer, President and Chairman of the Board
Terry Thompson

Terry Thompson

Chief Operating Officer
Andrew Ro

Andrew Ro

Chief Investment Officer and Director
Mark Corrao

Mark Corrao

Chief Financial Officer and Treasurer
Jason B. Terrell

Jason B. Terrell

Chief Medical Officer and Chief Scientific Officer
Richard Purcell

Richard Purcell

Executive Vice-President of Research & Drug Development
Show more

Generex Biotechnology Office Locations

Generex Biotechnology has offices in Burlington and Miramar
Burlington, CA (HQ)
4145 N Service Rd
Miramar, FL, US
10102 Usa Today Way #200
Show all (2)

Generex Biotechnology Financials and Metrics

Generex Biotechnology Revenue

Generex Biotechnology's revenue was reported to be $6.20 m in FY, 2019
USD

Revenue (Q3, 2020)

498.7k

Gross profit (Q3, 2020)

382.4k

Gross profit margin (Q3, 2020), %

76.7%

Net income (Q3, 2020)

(5.8m)

EBIT (Q3, 2020)

(3.6m)

Market capitalization (26-Feb-2021)

47.3m

Closing stock price (26-Feb-2021)

0.4

Cash (30-Apr-2020)

416.6k

EV

59.4m
Generex Biotechnology's current market capitalization is $47.3 m.
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Revenue

28.7k703.2k6.2m

Cost of goods sold

11.1k4.1m

Gross profit

17.5k2.1m

Gross profit Margin, %

61%33%
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q3, 2013Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q3, 2020

Revenue

9.9k5.0k7.0k2.2k700.0k1.7m3.4m1.1m721.7k498.7k

Cost of goods sold

3.3k3.6k2.2k870.6k2.0m1.3m133.6k116.3k

Gross profit

6.7k1.3k4.8k848.5k1.4m(172.0k)588.0k382.4k

Gross profit Margin, %

67%27%68%49%42%(16%)81%77%
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Cash

246.3k1.7m3.3m750.0k16.9k2.9m1.0m298.5k

Accounts Receivable

33.6k36.3k

Prepaid Expenses

200.6k98.3k201.3k51.2k8.1k21.9k96.3k275.7k

Inventories

10.0k12.1k363.0k
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Cash

1.1m544.8k1.2m37.0k1.1m406.6k3.1m4.2m1.6m925.9k52.4k31.8k47.2k37.1k2.3m2.0m1.6m2.4m2.4m1.4m540.3k269.1k416.6k

Accounts Receivable

1.7k175.0175.03.0m2.3m1.8m154.6k239.9k142.0k

Prepaid Expenses

193.6k1.5m296.3k116.3k187.3k68.5k102.4k45.5k99.8k49.0k52.0k5.2k8.1k11.1k293.3k227.0k161.7k193.2k286.4k218.8k451.3k

Inventories

500.6k500.6k22.7k12.0k12.0k12.0k838.7k1.1m250.0k727.3k861.1k911.0k
show all
Annual
USDFY, 2012FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017FY, 2018FY, 2019

Net Income

(9.5m)(8.6m)(1.4k)(2.2m)(3.2m)(76.8m)35.9m(11.0m)

Depreciation and Amortization

612.7k463.7k368.4k700.8k1.4m5.0k23.8k426.4k

Inventories

716.4k(11.1k)2.0k1.1m

Accounts Payable

(1.2m)123.6k(490.4k)(117.7k)1.1m899.8k872.2k9.3m
Quarterly
USDQ1, 2012Q2, 2012Q3, 2012Q1, 2013Q2, 2013Q3, 2013Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q3, 2017Q1, 2018Q2, 2018Q3, 2018Q1, 2019Q2, 2019Q3, 2019Q1, 2020Q2, 2020Q3, 2020

Net Income

336.4k(8.8m)(7.9m)(656.2k)(6.3m)(5.0m)(2.7m)270.9k(462.3k)(1.9m)(1.7m)(1.8m)(860.3k)(64.4m)27.5m17.7m21.1m17.8m5.4m(5.8m)(9.3m)(16.6m)(22.4m)

Depreciation and Amortization

163.7k320.1k472.1k117.0k234.6k349.0k191.8k203.4k291.4k52.7k123.1k194.2k2.3k1.2k2.0k17.5k25.7k378.2k550.3k203.3k407.1k609.0k

Inventories

216.0k215.8k716.4k1.6k2.0k2.0k2.0k(242.2k)(386.0k)(1.2m)(98.2k)(232.0k)(281.9k)

Accounts Payable

(13.9k)(617.8k)(1.3m)560.0k449.8k212.6k51.7k(449.9k)(378.3k)522.1k662.8k823.7k592.6k318.0k211.7k673.9k1.0m3.3m7.1m2.4m4.1m6.1m
show all
USDQ1, 2012

Debt/Equity

-0.3 x

Debt/Assets

0.3 x

Financial Leverage

-1.1 x
Show all financial metrics

Generex Biotechnology Cybersecurity Score

Cybersecurity ratingPremium dataset

B

82/100

Learn more about our premium products
SecurityScorecard logo

Generex Biotechnology Online and Social Media Presence

Generex Biotechnology's Trends

Embed Graph

Generex Biotechnology News and Updates

February 03, 2021

Generex Biotechnology Announces Call-in Details and Agenda for Shareholder Conference Call on Friday February 5, 2021 at 9:00 AM

The access information for the investor conference call is as follows: Domestic US/Canada - 1-(866) 342-8588Direct Toll / International - 1-(203) 518-9865 Program Title: Generex Biotechnology Conference Call Conference ID – 61174
November 12, 2020

Generex Biotechnology Announces Interview with Richard Purcell EVP of R&D on the Yo! Dr.Yo Show with an Update on the Ii-Key COVID Vaccine Program

Livestream Interview on Friday November 13 at 2 PM EST Livestream Interview on Friday November 13 at 2 PM EST
September 25, 2020

Generex Biotechnology Subsidiary NuGenHealth Contracts with Paradise Valley Family Medicine to Provide Chronic Care Management (CCM) and Remote Patient Monitoring (RPM) Services

-  NuGenHealth Software as a Service (SaaS) platform launch-  PVFM responds to COVID-19 with connected care solutions to serve their Medicare patient population
September 09, 2020

Generex Biotechnology Announces Analyst Report by Ari Zoldan at Seeking Alpha

Article Published on September 8, 2020:
August 13, 2020

Generex Biotechnology Subsidiary Olaregen Therapeutix Announces Publication on the Use of Excellagen® for Vascular Repair

MIRAMAR, Fla., Aug. 13, 2020 (GLOBE NEWSWIRE) -- Generex Biotechnology Corporation (www.generex.com) (OTCQB:GNBT) is pleased to  announce that physicians at Yale University School of Medicine and the VA Connecticut Healthcare System have published a paper in the Journal of Vascular Surgery Cases a…
July 27, 2020

Generex Biotechnology Announces That FDA has Accepted the Pre-IND Briefing Package for the Company’s Ii-Key-SARS-CoV-2 Vaccine and Will Provide a Written Response by August 24, 2020

FDA to provide written response with guidance on the proposed comprehensive clinical development program for Ii-Key-SARS-CoV-2 prophylactic peptide vaccine against COVID-19 FDA to provide written response with guidance on the proposed comprehensive clinical development program for Ii-Key-SARS-CoV-2 …
Show more

 Generex Biotechnology Frequently Asked Questions

  • Who are Generex Biotechnology key executives?

    Generex Biotechnology's key executives are Joseph Moscato, Terry Thompson and Andrew Ro.

  • How many employees does Generex Biotechnology have?

    Generex Biotechnology has 9 employees.

  • What is Generex Biotechnology revenue?

    Latest Generex Biotechnology annual revenue is $6.2 m.

  • What is Generex Biotechnology revenue per employee?

    Latest Generex Biotechnology revenue per employee is $689.3 k.

  • Who are Generex Biotechnology competitors?

    Competitors of Generex Biotechnology include RespireRx Pharmaceuticals, Akorn and CASI Pharmaceuticals.

  • Where is Generex Biotechnology headquarters?

    Generex Biotechnology headquarters is located at 4145 N Service Rd, Burlington.

  • Where are Generex Biotechnology offices?

    Generex Biotechnology has offices in Burlington and Miramar.

  • How many offices does Generex Biotechnology have?

    Generex Biotechnology has 2 offices.